Not available
Quote | ProQR Therapeutics N.V. (NASDAQ:PRQR)
Last: | $1.6599 |
---|---|
Change Percent: | 1.21% |
Open: | $1.64 |
Close: | $1.64 |
High: | $1.66 |
Low: | $1.6301 |
Volume: | 8,960 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | ProQR Therapeutics N.V. (NASDAQ:PRQR)
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
2024-05-11 17:57:09 ET ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast May 09, 2024 08:00 AM ET Company Participants Sarah Kiely - IR Daniel de Boer - Founder and CEO Gerard Platenburg - Chief Scientific Officer Conference Call Participants Jon ...
Message Board Posts | ProQR Therapeutics N.V. (NASDAQ:PRQR)
Subject | By | Source | When |
---|---|---|---|
Nice rebound! | KeepOn | investorshub | 04/15/2023 2:27:13 AM |
$0.4~ | Alan Brown | investorshub | 01/09/2023 12:10:35 AM |
Ya.... | Alan Brown | investorshub | 01/07/2023 4:48:06 AM |
znewcar1: $PRQR 63% v88,4M c2.70 f71,43M H3.1 ML1.13 LL.53 | znewcar1 | investorshangout | 12/22/2022 9:11:25 PM |
Eli Lilly sends ProQR 35% higher after expanding | subslover | investorshub | 12/22/2022 6:26:10 PM |
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...